Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Mustang Bio Inc.
DescriptionChimeric antigen receptor (CAR) T cells targeting interleukin-3 (IL-3) receptor alpha (CD123)
Molecular Target Interleukin-3 (IL-3) receptor alpha (CD123)
Mechanism of Action 
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat relapsed or refractory acute myeloid leukemia (AML)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today